Effects on cycle control and bodyweight of the combined contraceptive ring, NuvaRing, versus an oral contraceptive containing 30 microg ethinyl estradiol and 3 mg drospirenone.

@article{Milsom2006EffectsOC,
  title={Effects on cycle control and bodyweight of the combined contraceptive ring, NuvaRing, versus an oral contraceptive containing 30 microg ethinyl estradiol and 3 mg drospirenone.},
  author={Ian Milsom and I{\~n}aki Lete and A Bjertnaes and Kirsten Skinlo Rokstad and Ingela Lindh and Christian J. Gruber and Martin H. Birkhaeuser and Elizabeth Aubeny and Torben Knudsen and Carlo Bastianelli},
  journal={Human reproduction},
  year={2006},
  volume={21 9},
  pages={2304-11}
}
BACKGROUND The objective of this study was to compare cycle control, cycle-related characteristics and bodyweight effects of NuvaRing with those of a combined oral contraceptive (COC) containing 30 microg of ethinyl estradiol and 3 mg of drospirenone. METHODS A randomized, multicentre, open-label trial in which 983 women were treated (intent-to-treat population) with NuvaRing or the COC for 13 cycles. RESULTS Breakthrough bleeding or spotting during cycles 2-13 was in general less frequent… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 2 times over the past 90 days. VIEW TWEETS
29 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 29 extracted citations

Similar Papers

Loading similar papers…